EE301 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Lenvatinib for the Treatment of Advanced Second-Line Endometrial Cancer
Abstract
Authors
N Yfantopoulos I Gountas A Skroumpelos K Theiakos O Economou A Karokis